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Effect of Zelnate administered as a metaphylactic upon initial processing of high-risk, 
newly received beef calves on performance and morbidity 
Brady E. Martin1, Reagan N. Cauble1, Elizabeth B. Kegley1, and Jeremy G. Powell1 
1University of Arkansas Division of Agriculture, Fayetteville, AR, 72701 
Abstract 
Bovine respiratory disease (BRD) is the most prominent and costly ailment in the stocker 
cattle industry today, and its prevalence has not been diminished in the last thirty years. 
Therefore, the objective of this study was to investigate the effects of Zelnate, a DNA 
immunostimulant, administered upon arrival to calves (n = 261; initial body weight 253 ± 4.0 
kg), on morbidity and mortality, growth performance, and producer costs. Crossbred male beef 
calves were acquired and transported to the University of Arkansas stocker unit for a 42-d 
backgrounding period. Calves were allocated into two treatment groups: 1) Zelnate, DNA 
immunostimulant administered or 2) Control, in which no immunostimulant was administered. 
Animals were checked daily for signs of morbidity and treated. Records for growth performance, 
morbidity, and mortality were kept. Data were analyzed using the GLIMMIX procedures of 
SAS. Significance was declared at P < 0.05 and tendencies between 0.05 ≤ P < 0.10. Zelnate 
treated calves tended (P = 0.09) to have a lower relapse rate compared to control calves. Average 
daily gain was similar (P = 0.60) between the two treatment groups. The treatment cost for the 
Zelnate group was more expensive than the cost to treat the control group (P < 0.01). Overall, 
our findings indicate that Zelnate administered upon arrival to high risk calves did not improve 
morbidity rates nor reduce the need for antibiotic treatment for respiratory disease, or affect 
performance, however it tended to decrease relapse rate and did increase costs by $9.24 per calf. 
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Based upon these results, Zelnate does not appear to be an effective metaphylactic therapy for 
BRD in newly received cattle. 
Introduction and Literature Review  
 Physiological stress, commingling in sale barns, and numerous viral and bacterial 
pathogens are responsible for bovine respiratory disease (BRD), and it remains the leading cause 
of feedlot morbidity and mortality (Woolums et al., 2005). The economic losses the industry 
endures annually is upwards of $750 million (Griffin, 1997) and disease prevalence has remained 
unchanged for the last three decades (Miles, 2009). The portion of costs from BRD due to the 
combination of mortality and treatment costs is approximately 82% (Faber et al., 2000). Each 
individual treatment of this disease costs on average $23.60, for both small feedlot operations 
(1,000-7,999 head) and large feedlot operations (8,000 or more head) there was not a statistical 
difference in cost per case. This cost per case has nearly doubled since 1999 when it cost on average 
$12.59 to treat per case (USDA-APHIS, 2013). This is a troubling indication that BRD is trending 
upwards in cost quite rapidly. Part of this increase in cost isn’t solely medical treatment but also 
due to loss of value of the livestock form poorer feed efficiency, less average gain, and lower meat 
grade (Griffin, 1997). In the beef industry the reduced daily live weight gains from BRD means a 
longer finishing time, leading to increased production costs (Potter, 2015).  
Stocker-feedlot facilities are complex systems with small profit margins and cattle health 
affects every aspect of their day to day operation. The ability to effectively manage cattle health 
affects optimization of available pens and pastures, management of labor and facilities, 
performance of cattle, and ultimately profits (Sweiger, 2010). The direct costs of BRD alone 
highlight the reason why feedlot operator’s management strategies are frequently directed at 
minimizing the occurrence of this disease in their cattle (USDA-APHIS, 2013). However, despite 
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advances in veterinary medicine, animal husbandry, and animal welfare, BRD continues to be a 
major problem for producers (Gorden, 2010). Stressors from handling, weaning, commingling, 
transporting, and changes in environment and diet contribute substantially to the probability of an 
animal contracting BRD by suppressing the animal’s immune system. 
BRD is of multifactorial origin, onset of this disease depends on complex interactions 
between viruses, bacteria, the environment and the host (Faber et al., 2000). Most animals with 
healthy immune systems can fight off the initial viral infections, thus avoiding severe disease. 
However, cattle with immune suppression due to stress factors are not able to combat the initial 
viral infection (Powell, 2010) The usual scenario leading to the development of the disease 
involves the combination of an immunocompromised calf (usually due to stress), exposed to an 
immunosuppressive viral agent such as bovine virus diarrhea virus or bovine herpesvirus-1 
(infectious bovine rhinotracheitis virus). The establishment of a primary viral infection leads to 
the progressive development of BRD from the upper to the lower respiratory tract. This viral 
immunosuppression compromises the innate immune system and mucociliary escalator. This 
condition allows commensal bacterial pathogens to migrate and colonize the lower respiratory 
tract, leading to pulmonary compromise, inflammation, and gross pathology (Edwards, 2010). The 
main pathogenic bacteria responsible for colonization and replication inside the lower respiratory 
tract include Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni (Potter, 
2015). 
The early clinical signs commonly associated with BRD are nasal discharge, decreased 
appetite, lethargy, separation form the herd, a gaunt appearance, an increased respiratory rate and 
coughing. Animals often also have a rectal temperature of greater than 40.0 degrees Celsius and 
occasionally sores on the mouth and/or nose (Powell, 2010). Once an animal is infected with BRD 
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the immune system’s nutrient consumption increases dramatically. Rates of gluconeogenesis 
increase 150% to 200% during moderate infections, and the basal metabolic rate has been shown 
to increase 25% to 55% during periods of sepsis (Gorden & Plummer, 2010). If treatment of this 
disease is delayed, the number of deaths or chronically infected animals in the herd will likely 
increase. As it progresses, severe lung damage occurs from inflammation due to infection. Often, 
the lung damage caused by BRD is irreversible (Powell, 2010). Mortality rate of calves diagnosed 
and treated for BRD was 5.9% compared to .35% for those calves not diagnosed with BRD (Faber 
et al., 2000). Enteritis is the most common cause of death in BRD infected cattle, followed by 
pneumonia. Once an animal contracted enteritis or pneumonia the case fatality rate averaged 
11.18% and 17.9% respectively (Silva et al., 1996). 
A compounding difficulty in the process of successfully diagnosing BRD is it is quite 
difficult to accurately diagnose due to the nature of the disease and the nature of cattle themselves. 
Being a prey animal, cattle instinctively mask the clinical signs of sickness as a means of self-
preservation. For this reason, subclinical disease is difficult, if not impossible, to identify. Based 
on the usual subjective methods of first identifying BRD, identifying sick cattle is sometimes 
considered a learned skill or an art (Edwards, 2010). The difficulty accurately identifying all 
animals that require treatment is the reason many clinicians put a greater emphasis on prevention 
of BRD instead of treating the disease post-infection (Griffin, 1997). In fact, treatment of BRD 
post-infection may be inadequate to prevent significant production loses. One study found that 
almost 70% of cattle never treated for BRD had pulmonary lesions at slaughter that were indicative 
of the disease, indicating many infected cattle were never identified. If this finding is representative 
of the general cattle population, then the use of clinical signs as indicators of disease could be 
resulting in a large misclassification bias (Wittum 1996). These cattle were likely infected with a 
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less obvious subclinical infection of BRD, which leads to performance effects that have a similar 
devastating economic impact as the more easily recognizable clinical infection. The imprecision 
of clinical diagnosis of BRD strengthens the argument for mass medications, particularly when 
significant morbidity in a group is anticipated (Sweiger & Nichols, 2010). 
 A way to avoid the current increasing resistance of BRD inducing bacteria while treating 
subclinical animals is by improving the active immune system of cattle by administering herd-
wide vaccines. However, these vaccines often cause tissue injury and an inflammatory response at 
the injection site and reduced feed consumption upon successive vaccinations. These reactions 
lead to decreased carcass value due to having to remove inflamed or damaged tissue as waste and 
decreased gain to feed ratio that increases feed expenses for the producer. This issue of multiple 
vaccinations compounding these effects is profound in the stocker industry due to the lack of 
communication of specific vaccination schedules between locations, in fact some cattle may 
receive as many as six vaccinations during their life time, resulting in intense local reactions at the 
site of injection (Stokka et al., 1994). Nonetheless it must be acknowledged that this unknown 
history is not only a complicating and determining factor in cattle health but also an opportunity 
for the next owner of these calves to procure them at a discounted price relative to the market. 
These discounted prices are a major driver in profitability for producers in this segment of the 
industry (Sweiger & Nichols, 2010). Even when vaccines don’t damage carcass traits or feeding 
behavior, many pathogens and immune responses to these pathogens have been poorly 
characterized. As a result, it is difficult to develop effective vaccines to combat these pathogens 
(Babiuk, 2002).  
Other anti-infectives such as corticosteroids and non-steroidal anti-inflammatory drugs 
(NSAIDs) have been used as attempted treatments for BRD besides vaccines and antibiotics to 
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little avail. There is insufficient data to conclude a potential positive effect of NSAID use on the 
positive cost benefits of NSAIDs as treatments of BRD (Potter, 2015). The lack of effective 
treatments that do not cause rates of antibiotic resistance to increase has caused researchers to 
recommend future projects that examine the effectiveness of new types of vaccines that do not 
trigger similar immune responses as clostridial vaccines (Johnson, 2016).  
One possible novel solution that falls in line with these recommendations is use of the 
recently released DNA immunostimulant Zelnate (Bayer HealthCare LLC, Shawnee Mission, KS) 
that has resulted in decreased lung lesion scores in cattle exposed to the Mannheimia haemolytica 
bacteria (Nickell et al., 2016) and a reduction of clinical signs of BRD in high-risk cattle upon 
feedlot entry (Rogers et al., 2016). This pharmaceutical is intended to counteract the 
immunosuppressant effects of stress on stocker calves by stimulating the subjects’ innate immune 
system through exposing it to a liposome containing a non-specific DNA antigen that prepares the 
calf’s body to fight off a Mannheimia haemolytica infection. 
 The principle upon which polynucleotide immunostimulants like Zelnate are based is that 
the liposome is taken up by a cell, and if the appropriate promoters/enhancers are present, the genes 
encoded in the liposome are expressed and are translated to produce the encoded protein. Since 
these proteins are foreign, they induce an immune response in the animal. The great advantage of 
this approach, especially for viral antigens, is that the antigen is expressed endogenously and, 
therefore, all the posttranslational modifications are similar to those present during infection. As a 
result, the antigens are authentic, with all the conformational epitopes required for protection being 
expressed. To assist in elevating the immune response, the liposome contains built-in adjuvants in 
the form of CpG sequences. These sequences are critical in not only creating the cytokine micro-
environment required for induction of immunity, but also in providing the Th1±Th2 balance and 
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the long-term memory observed with DNA-based immunostimulants. A real advantage of DNA 
immunostimulants such as Zelnate is that they can induce immune responses in neonates even in 
the presence of passive antibody. This is a true advantage over conventional or genetically 
engineered vaccines. This observation is extremely encouraging since it will allow us to administer 
to animals at a very early age, a time when they are easy to handle, and this will ensure that they 
are fully protected at the time passive antibody decays (Babiuk, 2002). Also, the concern regarding 
typical vaccines negatively affecting growth performance or feeding behavior does not occur with 
Zelnate (Gaspers, 2016). This novel pharmaceutical has also been proven to be inactive on human 
and mouse toll-like receptor 9 in cell culture in both recombinant and natural cellular receptor 
settings despite the presence of numerous non-methylated CpG motifs in its plasmid DNA 
(Babiuk, 2002). 
Zelnate is designed to reduce the clinical instances of BRD and reduce the use of antibiotics 
while improving performance in high-risk, newly received beef calves. The objective of the current 
study is to evaluate the effect of metaphylactic administration of Zelnate on morbidity, mortality, 
and growth performance in newly received high-risk calves during a 42-d receiving period. The 
majority of calves treated for BRD are treated within the first 27 d of the feeding period (Buhman 
et al., 2000). 
 
Materials and Methods 
Animals 
 Crossbred male beef calves (n = 261; bulls = 129; steers = 132, initial body weight (BW) 
= 253 ± 4.0 kg) acquired from multiple local auction markets were shipped to the University of 
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Arkansas, Division of Agriculture, Stocker and Receiving Cattle Unit located near Fayetteville, 
AR. Calves were received on 3 separate dates (blocks) with 98, 82, and 81 calves arriving each of 
these days, respectively. For each arrival date, 4 pens were assigned randomly per treatment. 
Treatment pens were separated such that cattle on different treatments were not housed with fence-
line contact. Prior to study initiation, animal care and use procedures were approved by the 
University of Arkansas Care and Use Committee (approval #19018).  
Allocation and Arrival Procedures 
 Upon arrival on d 0, calves were weighed, assigned a unique ear tag for identification, 
tested for the prevalence of persistent infection with bovine viral diarrhea virus (PI-BVDV), and 
arrival castrate status was determined. No calves tested positive for PI-BVDV. Calves were 
stratified chute side by arrival castrate status using random allotment sheets so that cattle that 
arrived as steers and bulls were evenly distributed within pen across both treatments (8 pens/block; 
10 to 13 calves/pen) and pens were assigned randomly to 1 of 2 experimental treatments: 1) 
Zelnate, DNA immunostimulant metaphylactic administration (Zelnate, 2 mL intramuscularly 
(IM); Bayer HealthCare, Shawnee Mission, KS), 2) Control, in which calves received no 
immunostimulant. 
On d 0, calves were administered the appropriate experimental treatment, and all calves 
received a pentavalent modified-live virus vaccine for respiratory pathogens Titanium 5, Elanco 
Animal Health, Greenfield, IN), a clostridial-tetanus toxoid (Covexin 8, Merck Animal Health, 
Madison, NJ), and an injectable anthelmintic (Cydectin Injectable, Bayer HealthCare LLC). 
Calves were branded on the right hip and intact males were castrated via banding (California 
Bander, InoSol Co. LLC, El Centro, CA). Blood was also drawn through jugular venipuncture into 
vacuum tubes with a clot activated gel. Blood was centrifuged and serum stored at -20° C until 
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analyzed. Serum analysis of haptoglobin concentrations from d 0 and 14 were conducted using 
ELISA panels (Immunology Consultants Laboratory, Inc. ). Calves were revaccinated on d 14 with 
the same pentavalent modified-live virus respiratory vaccine and clostridial-vaccine.  
Housing and Diets 
 Calves were moved to their assigned 0.4-ha pens and provided 0.45 kg/d (as-fed basis) of 
a receiving supplement which was increased to 1.8 kg/d and provided 160 mg monensin after diet 
adaptation. Supplement was offered daily at 0800 and calves had ad libitum access to 
bermudagrass hay and water. 
Procedures 
 Body weights were measured on d 0, 14, 28, 41, and 42. Average daily gain was determined 
based on initial BW, two interim BW, and the average of the final 2 BW (d 41 and 42). 
Assessment and Treatment of Morbid Calves 
 During feeding, a pen rider blinded to experimental treatments observed cattle daily for 
signs of morbidity and a Clinical Attitude Score (CAS; 0 [normal] to 5 [moribund]; Table 1) was 
recorded. Calves that scored a 1 or greater were pulled, weighed, and rectal temperatures were 
recorded via digital thermometer (Model No. M216, GLA Agricultural Electronics; San Luis 
Obispo, CA), if temperature exceeded 40.0° C calves were treated according to a preplanned 
protocol. Animals with a CAS > 2 were treated regardless of rectal temperature. All calves 
qualifying for first-line BRD therapy were given enrofloxacin (Baytril 100, 5.7 mL/45 kg BW 
subcutaneously (SQ); Bayer HealthCare, LLC). Enrofloxacin was followed by a 2 d post-treatment 
interval (PTI) and if criteria for BRD persisted including CAS score and/or rectal temperature, 
florfenicol (Nuflor, 6.0 mL/45 kg BW SQ; Merck Animal Health) was the second antibiotic 
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administered. Following a 2 d PTI for florfenicol, calves eligible for a third antibiotic per 
previously stated criteria were administered ceftiofur hydrochloride (Excenel, 2.0 mL/45.5 kg BW 
SQ; Zoetis, Parsippany, NJ). 
 Morbidity data recorded included treatment date, rectal temperature at time of treatment, 
incidence of first, second, or third clinical respiratory disease, treatment cost, and mortality. Calves 
that were treated were housed in designated pens until deemed healthy upon the 48 h recheck. 
Relapse was defined as: of those calves treated with the first antibiotic, the percentage of calves 
that were treated with a second antibiotic. No animals died during the study. 
Statistical Analyses 
Performance data, morbidity response variables, and cost analysis were analyzed using the 
GLIMMIX procedure of SAS (SAS Inst. Inc., Cary, NC). Pen served as the experimental unit for 
all variables while calf served as the observational unit. The lone fixed effect in the model was 
treatment and block (arrival date) was considered to be the lone random effect. Least squares 
means were separated via the PDIFF option. Statistical significance was declared at P ≤ 0.05, and 
tendencies at 0.05 < P ≤ 0.10.  
Results and Discussion 
Growth Performance 
 Body weight was not affected by DNA immunostimulant inclusion at processing (Table 2; 
P ≥ 0.89). Initial BW were similar between control (252.2 kg) and Zelnate (252.7 kg; P = 0.93) 
treated calves. Body weights on d 14 were not different regardless of treatment (P = 0.89). Day 28 
BW were similar between treatment as control cattle were 278.6 kg and Zelnate cattle were 278.3 
kg, respectively (P = 0.95). Final BW did not differ by treatment with control and Zelnate cattle 
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weighing 294.1 and 293.5 kg (P = 0.91), respectively. Results were similar to findings by Gasper 
et al. (2016) which investigated the differences in 1) saline, and 2) MLV vaccine in combination 
with Mannheimia haemolytica, 3) Zelnate, and 4) MLV in combination with Mannheimia 
haemolytica and Zelnate and concluded that there were no differences in final BW or ADG across 
treatments. The addition of Zelnate did not affect BW. 
 Similarly, to growth performance, average daily gain (ADG) for the 42-d backgrounding 
period was not affected by the inclusion of a DNA immunostimulant (Table 2; P ≥ 0.32). From d 
0 to 14, ADG was 0.88 and 0.79 for control and Zelnate cattle respectively (P = 0.32). Average 
daily gain from d 14 to 28 was unaffected by treatment (P = 0.76). Similar ADG between 
treatments was observed from d 28 to 42 (P = 0.67). Overall ADG over the 42 study was not 
different between control cattle (1.00 kg/d) and Zelnate cattle (0.97 kg/d; P = 0.60). Zelnate did 
not have an effect on growth performance in newly received, high risk calves. A study 
investigating the effects of Zelnate compared to a saline control over a 70-d backgrounding period 
(Woolums et el., 2019) also reported no advantage in ADG. 
Morbidity 
 There were no chronically ill calves or mortalities in either treatment group. Percentage 
BRD morbidity for first treatment antibiotic (enrofloxacin) was similar between calves treated with 
the immunostimulant (56.5 %) and control calves (49.9 %; P = 0.31; Table 3) with days in which 
the first treatment was administered being similar (P = 0.72; Table 3). The percentages of calves 
treated with a second antibiotic (florfenicol) did not differ between treatments (P = 0.37) with days 
till second treatment occurring on day 13.2 and 12.9 for control and Zelnate calves, respectively 
(P = 0.91). Days until third treatment were similar (P = 0.41). Relapse percentage accounted for 
calves that were treated with a second antibiotic after being treated with the first treatment 
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antibiotic. The percentage of calves that relapsed tended to differ between treatments with 47.4 
and 32.2% for control and Zelnate calves, respectively (P = 0.09).  
Serum haptoglobin levels for both groups on d 0 (P = 0.40) and d 14 (P = 0.99) were 
similar. Rectal temperature was similar between control and Zelnate for calves treated for clinical 
BRD (Table 4; P ≥ 0.13). Regardless of first (P = 0.74), second (P = 0.13), or third (P = 0.71) 
antibiotic use, the inclusion of a DNA immunostimulant did not impact rectal temperatures for 
calves treated for BRD. Treating high risk calves upon arrival with Zelnate did not have an effect 
on morbidity variables.  
Economics 
 The cost of antibiotic treatments were analyzed. The cost of antibiotics including all 3 
treatment antibiotics used to treat clinical BRD was similar between control ($13.12) and Zelnate 
cattle ($12.40) for the 42-d study (Table 4; P = 0.72). Overall costs including antibiotic costs and 
the cost to treat with Zelnate upon arrival were greater ($22.36) compared to the antibiotic costs 
to treat control calves ($13.12; P < 0.01). 
Conclusions 
 The inclusion of Zelnate upon arrival had no impact on growth performance or the number 
of calves treated for BRD. During the 42-d backgrounding period, there were no differences in 
BW or ADG at any of the 14-d collection intervals. The percentage of calves treated for clinical 
signs of BRD with one or two antibiotics did not differ and calves on both treatments had similar 
days till antibiotic treatment. The cost to treat clinical signs of BRD were similar between control 
and Zelnate calves, however, when the cost Zelnate was incorporated, therapeutic costs became 
more expensive. In this study, the use of Zelnate as a metaphylactic treatment may have a limited 
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impact on performance and morbidity in high-risk, newly received calves for the 42-d period, at 
an increased cost to producers. There was a trend for a reduction in relapses and it is unknown 
whether there would be improved immunity when stocker calves are moved to the feedlot.  
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Table 1.  Clinical attitude score system used to diagnose bovine respiratory disease.  
CAS Diagnosis Clinical signs 
0 Normal No BRD clinical signs; calf is bright, alert and responsive when 
approached. 
1 Mild BRD Calf looks ill with BRD until approached; calf brightens, moves readily, 
and appears normal when approached. Calf may be mildly depressed and 
small amount of nasal and/or ocular discharge may be present.  
2 Moderate BRD Calf is obviously ill with BRD; when approached calf does not brighten 
up and moves slowly. Calf is moderately depressed and may exhibit 
dyspnea, considerable nasal and/or ocular discharge and coughing. 
3 Severe BRD Calf is severely ill with BRD; when approached calf stumbles or moves 
only with extreme coercion. Calf is severely depressed and may be 
anorexic and coughing with copious nasal discharge. 
4 Moribund Calf is moribund; recumbent and not able or willing to rise or get feed and 
water. 
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Table 2: Effect of Zelnate on growth performance in high-risk, newly received beef calves. 
 Treatment   
Item Control Zelnate SEM P- value 
Body weight, kg     
  Initial1 252.2 252.7 4.0 0.93 
  D 14 264.4 263.7 3.7 0.89 
  D 28 278.6 278.3 3.6 0.95 
  Final2 294.1 293.5 3.6 0.91 
Average daily gain, kg     
  D 0 to 14 0.88 0.79 0.07 0.32 
  D 14 to 28 1.02 1.04 0.06 0.76 
  D 28 to 42 1.10 1.14 0.08    0.67 
  Overall 1.00 0.97 0.03 0.60 
1Body weight upon arrival 
2Average of 2 consecutive day weights 

















Table 3:  Effect of Zelnate on percentage morbidity in high-risk, newly received beef calves. 
 Treatment   
Item Control Zelnate SEM P- value 
Morbidity, %     
  1st treatment1 49.9 56.5 0.04 0.31 
  2nd treatment1 23.6 18.3 0.04 0.37 
  3rd treatment1 6.0 1.5 0.2 0.12 
  Relapse2 47.4 32.2 0.6 0.09 
  Days till 1st treatment1 6.6 6.9 0.6 0.72 
  Days till 2nd treatment1 13.2 12.9 1.7 0.91 
  Days till 3rd treatment1 22.3 18.0 3.0 0.41 
Serum haptoglobin levels d 03 14.1           13.9 0.3 0.40 
Serum haptoglobin levels d 143 14.5 14.3 0.2 0.99 
11st treatment = Enrofloxacin, 2nd treatment = Florfenicol, 3rd treatment = Ceftiofur 
2Relapse = number of calves retreated after 1st treatment 
3Units = ng/mL  
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Table 4:  Effect of Zelnate on rectal temperature and antibiotic usage cost in high-risk, newly received beef 
calves. 
 Treatment   
Item1 Control Zelnate SEM P- value 
Rectal Temperature, °C     
  1st treatment 40.6 40.6 0.1 0.74 
  2nd treatment 40.4 40.7 0.2 0.13 
  3rd treatment 40.5 40.3 0.3 0.71 
Antibiotics     
Antibiotic cost, $/calf      13.12 12.40 1.5 0.74 
Antibiotics plus Zelnate, $/calf  13.12 22.36 1.5 <0.01 
11st treatment = Enrofloxacin, 2nd treatment = Florfenicol, 3rd treatment = Ceftiofur, Antibiotic costs = cost to treat 
calves, Antibiotics plus Zelnate = cost to treat calves in addition to Zelnate cost upon arrival 
